These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30887256)

  • 1. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
    Harbeck N; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Blackwell K
    Future Oncol; 2017 Jul; 13(16):1385-1393. PubMed ID: 28453299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Harbeck N; Lipatov O; Frolova M; Udovitsa D; Topuzov E; Ganea-Motan DE; Nakov R; Singh P; Rudy A; Blackwell K
    Future Oncol; 2016 Jun; 12(11):1359-67. PubMed ID: 27020170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
    BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
    Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
    Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
    Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006).
    Agarwala SS; Nagl U; Guo X; Bellon A; Heyn J; Dimova-Dobreva M; Shen YM; Schaffar G; Humphrey M; Mathieson N; Koptelova N; Gattu S
    Curr Med Res Opin; 2022 Jun; 38(6):999-1009. PubMed ID: 35392751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
    Gascón P; Harbeck N; Rapoport BL; Anderson R; Brueckmann I; Howe S; Aapro M
    Crit Rev Oncol Hematol; 2024 Apr; 196():104306. PubMed ID: 38401695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
    Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
    Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
    Harbeck N; Wang J; Otto GP; Gattu S; Krendyukov A
    Future Oncol; 2019 Apr; 15(12):1313-1322. PubMed ID: 30834780
    [No Abstract]   [Full Text] [Related]  

  • 18. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
    Bellon A; Wang J; Skerjanec A; Velinova M; Dickerson D; Sabet A; Ngo L; O'Reilly T; Tomek C; Schussler S; Schier-Mumzhiu S; Gattu S; Koch SD; Schelcher C; Dobreva M; Boldea A; Nakov R; Otto GP
    Br J Clin Pharmacol; 2020 Jun; 86(6):1139-1149. PubMed ID: 32022282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
    Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.
    Gattu S; Wang J; Bellon A; Schelcher C; Nakov R; Arani R
    Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1130-1141. PubMed ID: 34350732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.